arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

SELLAS Life Sciences Group, Inc.

SLS
$11.99 ▲ +0.31 (+2.65%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Bearish
auto_awesome

Analytical Summary

SELLAS Life Sciences Group, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -39.9%
FCF / Share $-0.26
Trailing P/E
Price / Book 25.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-26.86M
↑ +13.0%
FCF / Share Free cash flow per share
$-0.26
↑ +55.0%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
20
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters